Intellia Therapeutics, Inc.(NTLA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,784 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
NTLA Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Intellia Therapeutics, Inc. (NTLA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NTLA at 19.9/100 on a 32-signal composite quality model, placing it at rank #2,784 of 2,961 stocks — the bottom half of the AI-ranked universe. NTLA scores in the top quartile across institutional flow (99.1). Areas of concern include free cash flow (2.5) and profitability (2.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Intellia Therapeutics, Inc. reports quarterly revenue of $7.7M, net income of $-106.6M, free cash flow of $-84.9M. Top institutional holders of NTLA by reported 13-F value include ARK Investment Management, BlackRock, STATE STREET, based on the most recent SEC filings. NTLA trades on the Nasdaq exchange and files with the SEC under CIK 1652130. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NTLA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Intellia Therapeutics, Inc. directly from SEC EDGAR. Intellia Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 11 and 33 since 2021, currently 19.9 — an improving long-term trajectory across 65 quarterly and live scoring snapshots.
Revenue
Q2 2026
$7.7M
Net Income
Q2 2026
$-106.6M
Free Cash Flow
Q2 2026
$-84.9M
ROIC
Q2 2026
-62.0%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+16.9% YoYNet Income
+20.5% YoYOperating Income
+17.5% YoYEPS (Diluted)
+27.4% YoYTotal Assets
-29.3% YoYOp. Cash Flow
-13.1% YoYFree Cash Flow
-11.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $67.7M +16.9% | $57.9M +59.6% | $36.3M -30.4% | $52.1M +57.7% | $33.1M -43.0% | $58.0M |
| Net Income | $-412.7M +20.5% | $-519.0M -7.9% | $-481.2M -1.5% | $-474.2M -77.0% | $-267.9M -99.6% | $-134.2M |
| Operating Income | $-441.0M +17.5% | $-534.3M -3.7% | $-515.3M -12.5% | $-458.2M -71.1% | $-267.9M -96.1% | $-136.6M |
| EPS (Diluted) | $-3.81 +27.4% | $-5.25 +3.1% | $-5.42 +12.0% | $-6.16 -63.0% | $-3.78 -57.5% | $-2.40 |
| Total Assets | $842.1M -29.3% | $1.19B -8.5% | $1.30B -14.4% | $1.52B +17.4% | $1.29B +91.4% | $676.3M |
| Operating Cash Flow | $-394.7M -13.1% | $-348.9M +11.5% | $-394.1M -18.2% | $-333.3M -48.1% | $-225.0M -350.9% | $-49.9M |
| Free Cash Flow | $-395.9M -11.6% | $-354.7M +13.1% | $-408.1M -17.7% | $-346.8M -45.9% | $-237.8M -344.5% | $-53.5M |
Get alerted when NTLA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Intellia Therapeutics, Inc. including:
Top Institutional Holders of NTLA
ARK Investment Management LLC
$285.5M16,875,684 shBlackRock, Inc.
$260.7M15,409,023 shSTATE STREET CORP
$156.3M9,234,987 shVANGUARD PORTFOLIO MANAGEMENT LLC
$124.1M7,332,401 shD. E. Shaw & Co., Inc.
$109.0M6,443,323 shVANGUARD CAPITAL MANAGEMENT LLC
$102.0M6,028,586 shTWO SIGMA INVESTMENTS, LP
$88.6M5,235,348 shFMR LLC
$80.8M4,773,034 shRA CAPITAL MANAGEMENT, L.P.
$76.6M4,526,926 shREGENERON PHARMACEUTICALS, INC.
$62.7M3,702,995 sh
| Fund | Value | Shares |
|---|---|---|
| ARK Investment Management LLC | $285.5M | 16,875,684 |
| BlackRock, Inc. | $260.7M | 15,409,023 |
| STATE STREET CORP | $156.3M | 9,234,987 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $124.1M | 7,332,401 |
| D. E. Shaw & Co., Inc. | $109.0M | 6,443,323 |
| VANGUARD CAPITAL MANAGEMENT LLC | $102.0M | 6,028,586 |
| TWO SIGMA INVESTMENTS, LP | $88.6M | 5,235,348 |
| FMR LLC | $80.8M | 4,773,034 |
| RA CAPITAL MANAGEMENT, L.P. | $76.6M | 4,526,926 |
| REGENERON PHARMACEUTICALS, INC. | $62.7M | 3,702,995 |
Companies Similar to NTLA
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Relay Therapeutics, Inc.
C4 Therapeutics, Inc.
Prelude Therapeutics Inc
Editas Medicine, Inc.
CRISPR Therapeutics AG
Absci Corp
Celldex Therapeutics, Inc.
RECURSION PHARMACEUTICALS, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put NTLA on your watchlist
Track score changes the day Intellia Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NTLA a good stock to buy?
13F Pro's AI-powered analysis of Intellia Therapeutics, Inc. (NTLA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NTLA are available on the NTLA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NTLA is classified as a small company.
Which hedge funds own NTLA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NTLA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Intellia Therapeutics, Inc.'s investment landscape.